1208PSafety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & amp; MSI-H cohorts

ConclusionsNo safety concerns have been observed with the combination therapy which is showing early signs of clinical efficacy. Enrollment is expected to continue to Stage 2 of the Simon 2 stage design.Clinical trial identificationNCT03836352.Legal entity responsible for the studyIMV Inc.FundingIMV Inc.DisclosureL.D. MacDonald: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. S. Fiset: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. Y.M. Bramhecha: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. M. Chaney: Full / Part-time employment: Merck& Co. G.N. Rosu: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research